-
2 weeks ago | 
clinicaltrialsarena.com | Frankie Fattorini
Artificial intelligence (AI) is revolutionising clinical trials, offering ways to improve the consent process, but concerns regarding the complete reliability of the technology for sensitive tasks persist. The limitations of AI to enhance trial participant engagement, and how it may overcome these, were outlined by Blanka Hezelova, associate director at GSK on 11 June.
-
2 weeks ago | 
clinicaltrialsarena.com | Frankie Fattorini
While encouraged by revised regulations aimed at boosting UK clinical studies, experts say busy schedules of NHS workers present a major bottleneck to the country’s ability to conduct cancer trials. An expert panel said the nation’s doctors and nurses have limited time or incentive to better support clinical trials through the National Health Service (NHS).
-
3 weeks ago | 
pharmaceutical-technology.com | Frankie Fattorini
First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma space. First clinical data presented at ASCO 2025 show a 100% response rate with the trispecific antibody JNJ-5322 among anti-BCMA/-GPTC5D-naïve r/r MM patients.
-
3 weeks ago | 
pharmaceutical-technology.com | Frankie Fattorini
The FDA set a PDUFA date in late 2025 as ziftomenib led to significant disease response in patients with common subtype of AML. The FDA has set a 30 November 2025 PDUFA date for approval of ziftomenib in NMP1-m r/r AML. Photo by SOPA Images/LightRocket via Getty Images A November 2025 PDUFA date has been set for Kura Oncology’s oral acute myeloid leukaemia (AML) drug ziftomenib following the unveiling of positive Phase II data.
-
3 weeks ago | 
pharmaceutical-technology.com | Frankie Fattorini
Can pharma tariffs “Make America Manufacture Again”? As President Trump continues to signal import tariffs on pharmaceuticals to bolster US manufacturing, experts warn this could hike costs…
-
3 weeks ago | 
clinicaltrialsarena.com | Frankie Fattorini
Amgen’s Nplate (romiplostim) has demonstrated efficacy in treating thrombocytopaenia among gastrointestinal (GI) cancer patients, as Phase III RECITE results are presented at ASCO 2025. In the Phase III RECITE trial (NCT03362177), Nplate limited the modification of immunosuppressive therapies while improving platelet response compared to placebo, as per the abstract unveiled at the 2025 American Society of Clinical Oncology (ASCO) conference in Chicago, Illinois.
-
3 weeks ago | 
pharmaceutical-technology.com | Frankie Fattorini
The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study. J&J’s cell therapy Carvykti consistently improved survival among high risk multiple myeloma patients. Photo by Cristina Arias/Cover via Getty Images Updated analysis showed Carvykti (ciltacabtagene autoleucel) improved survival for multiple myeloma patients regardless of their cytogenetic risk or prior lines of therapy.
-
4 weeks ago | 
pharmaceutical-technology.com | Frankie Fattorini
Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC. Pfizer’s Braftovi cur the risk of death in first-line combination therapy for BRAF V600E mCRC. Photo by SOPA Images / LightRocket via Getty Images.
-
1 month ago | 
clinicaltrialsarena.com | Frankie Fattorini
Representatives of industry and regulation will meet in June to discuss paths forward for the UK’s clinical trials sector following its recent reform and revitalisation. Delegates convene in London on 10–11 June at the 12th annual Outsourcing in Clinical Trials UK & Ireland conference to explore the challenges, innovations, and opportunities of trial outsourcing.
-
1 month ago | 
pharmaceutical-technology.com | Frankie Fattorini
Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs. Biopharma braces for Trump’s tariffs aimed at bringing manufacturing back to the US. Photo by Bloomberg/Bloomberg via Getty Images. As President Trump continues to signal import tariffs on pharmaceuticals to bolster US manufacturing, experts warn this could hike costs and crush biotech, but also spur reconsideration of biopharma production.
